Shanghai Miracogen Inc.

🇨🇳China

Country: 🇨🇳China

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

A Study of MRG002 in the Treatment of Patients With HER2-positive Advanced Solid Tumors

Phase 1

Conditions: Advanced Solid Tumor

Interventions: Drug: MRG002

First Posted Date: 2021-06-28

Last Posted Date: 2021-12-03

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 74

Registration Number: NCT04941339

Locations: 🇨🇳
Shanghai Oriental Hospital, Shanghai, Shanghai, China

A Study of MRG002 in the Treatment of Patients With HER2-positive Unresectable Locally Advanced or Metastatic Breast Cancer

Phase 2

Recruiting

Conditions: Metastatic Breast Cancer
Advanced Breast Cancer

Interventions: Drug: MRG002
Drug: Trastuzumab Emtansine for Injection

First Posted Date: 2021-06-14

Last Posted Date: 2023-03-17

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 350

Registration Number: NCT04924699

Locations: 🇨🇳
Anhui Provincial Hospital, Hefei, Anhui, China
🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳
Peking Union Medical College Hospital, Beijing, Beijing, China

and more 16 locations

A Study of MRG003 in Patients With Advanced Solid Tumors

Phase 1

Completed

Conditions: Advanced Solid Tumors

Interventions: Drug: MRG003

First Posted Date: 2021-04-30

Last Posted Date: 2021-04-30

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 61

Registration Number: NCT04868344

Locations: 🇨🇳
Sun Yat-sen University Cancer Center, Guangzhou, Guangdong, China

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Phase 2

Conditions: Recurrent or Metastatic Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: MRG003

First Posted Date: 2021-04-30

Last Posted Date: 2021-04-30

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 120

Registration Number: NCT04868162

Locations: 🇨🇳
Shanghai East Hospital, Shanghai, Shanghai, China

A Study of MRG004A in Patients With Tissue Factor Positive Advanced or Metastatic Solid Tumors

Phase 1

Recruiting

Conditions: Advanced or Metastatic Solid Tumors

Interventions: Drug: MRG004A

First Posted Date: 2021-04-13

Last Posted Date: 2022-09-08

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 181

Registration Number: NCT04843709

Locations: 🇨🇳
The First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, Zhejiang, China
🇺🇸
Memorial Sloan Kettering 60th Street Outpatient Center, New York, New York, United States
🇺🇸
Chao Family Comprehensive Cancer Center, Orange, California, United States

and more 6 locations

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2

Recruiting

Conditions: Advanced or Metastatic Biliary Tract Cancer

Interventions: Drug: MRG003

First Posted Date: 2021-04-09

Last Posted Date: 2021-12-29

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 80

Registration Number: NCT04838964

Locations: 🇨🇳
The First Affiliated Hospital of Xiamen University, Xiamen, Fujian, China
🇨🇳
The First Affiliated Hospital of Zhengzhou University, Zhengzhou, Henan, China
🇨🇳
Bethune First Hospital of Jilin University, Changchun, Jilin, China

and more 4 locations

A Study to Evaluate the Efficacy and Safety of MRG003 in Patients With EGFR-Positive Advanced Non-Small Cell Lung Cancer

Phase 2

Conditions: Carcinoma, Non-Small-Cell Lung

Interventions: Drug: MRG003

First Posted Date: 2021-04-09

Last Posted Date: 2021-04-09

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 90

Registration Number: NCT04838548

Locations: 🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China

A Study of MRG002 in the Treatment of HER2-positive Unresectable Locally Advanced or Metastatic Urothelium Cancer

Phase 2

Conditions: Locally Advanced Urothelial Cancer
Metastatic Urothelial Carcinoma

Interventions: Drug: MRG002

First Posted Date: 2021-04-09

Last Posted Date: 2021-12-14

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 58

Registration Number: NCT04839510

Locations: 🇨🇳
The Second Hospital of Anhui Medical University, Hefei, Anhui, China
🇨🇳
Cancer Hospital Chinese Academy of Medical Sciences, Beijing, Beijing, China
🇨🇳
Anhui provincial Cancer Hospital, Hefei, Anhui, China

and more 33 locations

A Study of MRG002 in the Treatment of HER2-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Phase 2

Conditions: Advanced or Metastatic Biliary Tract Cancer

Interventions: Drug: MRG002

First Posted Date: 2021-04-08

Last Posted Date: 2021-12-10

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 86

Registration Number: NCT04837508

Locations: 🇨🇳
Harbin Medical University Cancer Hospital, Harbin, Heilongjiang, China
🇨🇳
The first affiliated hospital of bengbu medical college, Bengbu, Anhui, China
🇨🇳
Henan Cancer Hospital, Zhengzhou, Henan, China

and more 4 locations

A Study of MRG002 in the Treatment of Patients With HER2-low Locally Advanced or Metastatic Breast Cancer (BC)

Phase 2

Recruiting

Conditions: Advanced or Metastatic Breast Cancer

Interventions: Drug: MRG002

First Posted Date: 2021-02-05

Last Posted Date: 2022-09-07

Lead Sponsor: Shanghai Miracogen Inc.

Target Recruit Count: 66

Registration Number: NCT04742153

Locations: 🇨🇳
Fifth Medical Center of PLA General Hospital, Beijing, Beijing, China
🇨🇳
The Fourth hospital of Hebei Medical University, Shijiazhuang, Hebei, China

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy